Report efficacy and safety data from the combination escalation cohort
Delivered after the deadline (4 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- 4 Jan 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Efficacy and safety data from the combination escalation cohort are expected to be reported in the second half of 2021”
What we found
Evidence strength A What the grades mean
The company announced initial results from the combination dose escalation cohort of INBRX-106 on January 4, 2022, which was after the second half of 2021 deadline.
-
A Inhibrx, Inc. 8-K filed 2022-01-04
“SAN DIEGO, January 4, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced initial results from Part 3 (combination dose escalation) of the 4-part Phase 1 trial of INBRX-106” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Efficacy and safety data for INBRX-106 combination cohort
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Inhibrx, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C739614-021095 · Corrections policy